ZERIA PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,078 JPY | +2.82% |
|
+1.76% | +3.02% |
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.8 for the current year.
- The company has a low valuation given the cash flows generated by its activity.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.02% | 568M | - | ||
| +20.45% | 43.39B | B- | ||
| +19.44% | 22.01B | B+ | ||
| +18.44% | 15.46B | - | ||
| +25.55% | 14.93B | B+ | ||
| +60.87% | 13.13B | B | ||
| -0.05% | 6.79B | - | - | |
| -15.02% | 6.36B | B+ | ||
| -8.87% | 5.73B | - | - | |
| +10.57% | 5.43B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4559 Stock
- Ratings Zeria Pharmaceutical Co., Ltd.
